VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2014 | Phase Ib shows pembrolizumab elicits complete or partial remission in Hodgkin lymphoma

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Craig Moskowitz (Memorial Sloan Kettering Cancer Center, New York, NY) discusses the preliminary results of a phase Ib study evaluating the PD-1 inhibitor, pembrolizumab, in patients with classical Hodgkin lymphoma after brentuximab vedotin failure.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter